COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. Methods Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. Results Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir. Conclusions This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART. To read more- https://link.springer.com/article/10.1007/s15010-020-01438-z

6 Likes

LikeAnswersShare
IT INDICATES THAT TENOFOVIR, ART REGIMEN. IS MUCH SAFER THAN DARUNAVIR....... REGIMEN.... AND PATIENTS OF HIV ARE DOING BETTER WITH TENOFOVIR, ALTHOUGH THEY ARE COVID INFECTED AS WELL..... KNOWLEDGEABLE PIECE OF INFORMATION BUT NEED FURTHER ELABORATION......... THANKS A LOT DR. PATIL.
Good observation and trail on few pt can't be concluded as alternate medication.thanks for sharing and updating. AID patients are more prone and their life is at maximum risk because of immunosuppressed deficiency.
Informative